Moving away from niche markets, Spectrum Pharmaceuticals has agreed to sell seven FDA-approved haematology and oncology assets to Acrotech Biopharma, a subsidiary of Aurobindo Pharma. Six of the seven are marketed products which generated total sales in excess of US$100 M for Spectrum in 2017. The deal continues Aurobindo’s deal spree to bolster its global presence after acquiring Apotex International’s generic and OTC businesses in the EU and Novartis’ Sandoz generic oral solids and dermatology business in the US.